A diagnostic challenge arises because of the positive nuclear reaction to β-catenin, which is the marker of a somatic point mutation of the β-catenin gene (CCTNB), a driving mutation in more than 90% of SPN, but also present in most pancreatoblastomas and in 15% of pancreatic neuroendocrine neoplasms of higher stage (III/IV) but not in lower stage neoplasms.19,20 That is the reason why the adjunctive immunohistochemical staining to SOX11 is recommended, which is positive in SPNs and negative in normal pancreatic tissue and in neuroendocrine neoplasms. The gene discussed is SOX11; the disease is neoplasm.